CAN-med Healthcare

canmedhealthcare.com

Can-med Healthcare, a Canadian owned division of IMP Group Ltd., is a value-added distributor of medical and surgical products, health imaging, dental mobility and home healthcare products and services. Headquartered in Bedford, Nova Scotia, and established over forty years ago, CAN-med Healthcare has nine locations throughout Canada to service the local medical and dental communities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

news image

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More

Pharma Tech

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

news image

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More

Business Insights

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More

Business Insights, PHARMA TECH

TONIX PHARMACEUTICALS TO OBTAIN AN EXCLUSIVE LICENSE FROM COLUMBIA UNIVERSITY

Tonix Pharmaceuticals | February 14, 2023

news image

On February 13, 2023, Tonix Pharmaceuticals, a leading clinical-stage biopharmaceutical firm, announced that it has exercised an option to acquire an exclusive license from Columbia University to develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the prophylaxis or treatment of SARS-CoV-2 infection. COVID-19 is caused by SARS-CoV-2. Tonix Pharmaceuticals and Columbia University announced a research collaboration and option agreement in 2020...

Read More
news image

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More
news image

Pharma Tech

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More
news image

Business Insights

SIMULATIONS PLUS COLLABORATES WITH MULTINATIONAL PHARMACEUTICAL COMPANY TO PROVIDE MODELING & SIMULATION SUPPORT FOR COVID-19 TREATMENT

Simulations Plus, Inc | June 24, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound. Early in the COVID-19 pandemic, the pharma...

Read More
news image

Business Insights, PHARMA TECH

TONIX PHARMACEUTICALS TO OBTAIN AN EXCLUSIVE LICENSE FROM COLUMBIA UNIVERSITY

Tonix Pharmaceuticals | February 14, 2023

On February 13, 2023, Tonix Pharmaceuticals, a leading clinical-stage biopharmaceutical firm, announced that it has exercised an option to acquire an exclusive license from Columbia University to develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the prophylaxis or treatment of SARS-CoV-2 infection. COVID-19 is caused by SARS-CoV-2. Tonix Pharmaceuticals and Columbia University announced a research collaboration and option agreement in 2020...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us